Finance Watch: Gossamer Works Around The Shutdown To Price Its $230m IPO

Gossamer Bio Inc. emerged from stealth mode with a lot of fanfare in 2018, revealing a $100m Series A venture capital round in January and a $230m Series B round in July. And it appears that the company's foray into the stock market – during a US government shutdown that kept the Securities and Exchange Commission (SEC) from processing new public offerings – will be notable as well.

San Diego-based Gossamer indicated in a Dec. 21 SEC filing that it intended to raise up to $264.5m in a forthcoming initial public offering to fund its drug development activities in autoimmune and inflammatory diseases, allergies and cancer. (Also see "IPO Update: Returns Run Red For Most Biopharma Firms That Went Public In The US Last Year" - Scrip, 5 January, 2019